BEHMUELLER, Manuel, TSELIS, Nikolaos, ZAMBOGLOU, Nikolaos, ZOGA, Eleni, BALTAS, Dimos, RÖDEL, Claus und CHATZIKONSTANTINOU, Georgios, 2022. High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer. oncological outcomes after a median 15-year follow-up. Freiburg: Universität.
Elsevier - Harvard (with titles)Behmueller, M., Tselis, N., Zamboglou, N., Zoga, E., Baltas, D., Rödel, C., Chatzikonstantinou, G., 2022. High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer. oncological outcomes after a median 15-year follow-up. Universität, Freiburg. https://doi.org/10.3389/fonc.2021.770959
American Psychological Association 7th editionBehmueller, M., Tselis, N., Zamboglou, N., Zoga, E., Baltas, D., Rödel, C., & Chatzikonstantinou, G. (ca. 2022). High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer. oncological outcomes after a median 15-year follow-up [Cd]. Universität. https://doi.org/10.3389/fonc.2021.770959
Springer - Basic (author-date)Behmueller M, Tselis N, Zamboglou N, Zoga E, Baltas D, Rödel C, Chatzikonstantinou G (2022) High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer. oncological outcomes after a median 15-year follow-up. Universität, Freiburg
Juristische Zitierweise (Stüber) (Deutsch)Behmueller, Manuel/ Tselis, Nikolaos/ Zamboglou, Nikolaos/ Zoga, Eleni/ Baltas, Dimos/ Rödel, Claus/ Chatzikonstantinou, Georgios, High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer. oncological outcomes after a median 15-year follow-up, Freiburg 2022.